COST COMPARISON OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE VERSUS PEMETREXED AND CISPLATIN THERAPY IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL CANCER IN GERMANY - AN UPDATED ANALYSIS

被引：0

作者：

Bischoff, H. G. ^{[1
]}

Hermes, A. ^{[2
]}

Heigener, D. F. ^{[2
]}

Cesaro-Tadic, S. ^{[3
]}

Walzer, S. ^{[4
]}

Nuijten, M. ^{[5
]}

机构：

[1] Thoraxklin, Heidelberg, Germany

[2] Krankenhaus Grosshansdorf, Grosshansdorf, Germany

[3] F Hoffmann Roche Pharmaceut AG, Basel, Switzerland

[4] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland

[5] Inst Med Technol Assessment, Rotterdam, Netherlands

来源：

VALUE IN HEALTH | 2010年 / 13卷 / 03期

关键词：

D O I：

10.1016/S1098-3015(10)72171-9

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A39 / A39

页数：1

共 50 条

[1] INDIRECT COMPARISON OF EFFICACY, SAFETY, AND COST: PEMETREXED/CISPLATIN VERSUS BEVACIZUMAB/GEMCITABINE/CISPLATIN IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Orlando, Mauro
Barraclough, Helen
Orlov, Sergey
Rajan, Narayan
Davey, Peter
Kanivets, Yana
Han, Baoguang
Brnabic, Alan
[J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1232 - S1233
[2] An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer
Nuijten, Mark J. C.
Aultman, Rick
de Castro Carpeno, Javier
Vergnenegre, Alain
Chouaid, Christos
Walzer, Stefan
Siebert, Uwe
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (11) : 2193 - 2201
[3] The cost-effectiveness of bevacizumab plus cisplatin and gemcitabine (BCG) compared with pemetrexed plus cisplatin (PC) induction treatment of advanced non-squamous non-small cell lung cancer (NSCLC) in Germany.
Bischoff, H.
Hermes, A.
Gatzemeier, U.
Heigener, D. F.
Cesaro-Tadic, S.
Walzer, S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[4] An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia
Chang, John Wen-Cheng
Thongprasert, Sumitra
Wright, Elaine
Tsang, Kenneth
Kim, Heung Tae
Ahn, Myung-Ju
Kim, Joo-Hang
Kang, Jin Hyoung
Kim, Sang-We
Walzer, Stefan
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 : 13 - 21
[5] A cost effectiveness analysis of bevacizumab plus cisplatin and gemcitabine (BCG) compared with induction pemetrexed plus cisplatin (iPC) for the treatment of advanced or recurrent non-small cell cancer (NSCLC) in Germany
Bischoff, Helge
Heigner, David
Wiesner, Christof
Walzer, Stefan
[J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S666 - S667
[6] THE COSTS OF TREATING PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL CANCER (NSCLC) WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE COMPARED WITH PEMETREXED PLUS CISPLATIN IN INDUCTION AND MAINTENANCE THERAPY IN GERMANY AND ITALY
Nuijten, M.
[J]. VALUE IN HEALTH, 2009, 12 (03) : A41 - A41
[7] A COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH PEMETREXED PLUS CISPLATIN (PC) FOR THE TREATMENT OF ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
Bischoff, H. G.
Heigener, D.
Wiesner, C.
Walzer, S.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A273 - A273
[8] AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
Walzer, S.
de Castro Carpeno, J.
Vergnenegre, A.
Chouaid, C.
Heigener, D.
Bischoff, H. G.
Aultman, R.
Siebert, U.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A258 - A258
[9] A cost analysis of treatment with bevacizumab plus cisplatin and gemcitabine (BCG) versus cetuximab plus vinorelbine and cisplatin (CVC) in patients with advanced or recurrent non-small cell lung cancer (NSCLC) in Germany
Heigener, D. F.
Wiesner, C.
Aultman, R.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[10] Analysis of cost-effectiveness of Bevacizumab plus cisplatin and gemcitabine (BCG) compared to an induction therapy with pemetrexed plus cisplatin (PC) in advanced or recurrent non-small cell lung cancer (NSCLC)
Bischoff, H.
Heigener, D.
Wiesner, C.
Walzer, S.
[J]. ONKOLOGIE, 2010, 33 : 131 - 132

← 1 2 3 4 5 →